Neuss (ots) - In der kommenden Legislaturperiode - somit ab 2018 - soll das E-Health-Gesetz um einen zweiten ...
Helsinn and Tánaiste announce new R&D Centre-of-excellence at Helsinn in Dublin
Investment in line with the Government and IDA strategy for R&D
Lugano, Switzerland/Dublin, Ireland (ots) - Helsinn together with the Irish Tánaiste and Minister for Enterprise, Trade and Employment Mary Coughlan TD, today announced, that Helsinn Holding S.A., a privately owned pharmaceutical company, is to establish a Centre-of-excellence in Research and Development for Oral Solid Dosage (OSD) at its Helsinn Birex Pharmaceuticals facility, one of four businesses at its site at Mulhuddart, Dublin. The investment of over ¤13 million which is supported by Government through IDA Ireland is anticipated to create 10 high-value research positions. Helsinn's core business is the in-licensing of late-stage pharmaceutical compounds in therapeutic niche areas for development and subsequent commercial manufacture and distribution. The company is primarily active in oncology supportive care, anti-inflammatory and gastrointestinal treatments. The investment is part of Helsinn's strategic decision to strengthen its in-house development capability.
The Tánaiste said "This investment will establish the Irish
operation as the Centre of Knowledge and Learning for OSD products in
the Helsinn Group and also the launch site for new products within
its portfolio. Strategically it is very significant for the Irish
operation, putting it at the core of Helsinn's R&D activities. The
investment is very much in line with the Government and IDA strategy
of transformation of existing Irish operations of international
companies, particularly into R&D and knowledge-based activities."
Helsinn's Irish operation was established in 1990, when it acquired
Birex Pharmaceuticals in Dublin. To-date Helsinn has invested a total
of over ¤55 million in Ireland and continuously invests in its plants
in order to maintain high quality and safety, to increase overall
production capacity and to offer its partners up-to date products,
technologies and services. It now employs a total of 210 people at
its four separate businesses - Helsinn Birex Pharmaceuticals, Helsinn
Chemicals Ireland and a sales and marketing company, Helsinn Birex
Therapeutics with its Ergha Healthcare division. Riccardo Braglia,
Chief Executive Officer of the Helsinn Group said, "This new
investment in R&D is another important step for the Irish operation
and will be of significant benefit for the future of our
international business, with the aim of centralising in the new plant
any scientific development for Oral Solid Dosage products".
Helsinn, a family owned company headquartered in Lugano, Switzerland, was established in 1976. It employs 450 people between its operations in Switzerland, Ireland and USA and supplies its products to 75 countries.
About Helsinn in Ireland
Helsinn has operated in Ireland since 1990 and its Irish manufacturing facilities are EU certified for manufacture of pharmaceutical products and were successfully inspected by the US Food and Drug Administration last year. The companies manufacture and package the group's products in compliance with EU, US FDA and all major international health and environmental requirements, thus guaranteeing Helsinn's clients the highest possible assurance of quality and reliability.
ots Originaltext: Helsinn Healthcare SA
General Manager, Helsinn Birex Pharmaceuticals
Department of Enterprise
Trade and Employment Press Office
Brendan Kenny, Press & PR